Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus gemcitabine in advanced soft-tissue sarcomas
2024-514827-40-00Phase 2Withdrawn
- Sponsor
- SELNET
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selinexor and Gemmis in leiomyosarcoma (LMS) and malignant peripheral nerve sheath tumor (MPNST), sponsored by SELNET. Primary endpoints: Dose Limiting Toxicities (DLTs) in first cycle (Phase I) and Progression-free survival rate at 6 months (PFSR) (Phase II). Planned start Aug 2024; status: withdrawn.
02
Drugs
selinexorGemmis
03
Conditions
leiomyosarcoma (LMS)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on 2024-514827-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514827-40-00.